35 results about "Motor disorder" patented technology

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and / or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

The invention discloses an application of rapamycin in preparation of a composition for treating a hereditary spastic paraplegia SPG subtype. The rapamycin can obviously improve the motion disorder and pathological injury phenotype of an SPG80 subtype mammal model, improve the lysosome function and promote the autophagy process through mTOR inhibition, provides specific intervention for nerve cell apoptosis and a glial cell abnormal activation mechanism caused by UBAP1 deletion, fills the blank that no effective treatment means exists for the SPG subtype, and has a good application prospect. A theoretical basis is provided for clinical treatment of patients, and a reference is provided for other SPG variations (such as SPG3A).

This invention belongs to the field of animal model technology, specifically disclosing a method for constructing a primary ciliary motor disorder hydrocephalus model, comprising the following steps: screening benzimidazole as a modeling agent; administering benzimidazole solution to experimental animals and setting up a blank control group; conducting experimental verification through pathological morphology and behavioral methods; if the experimental animals show significant ventricular enlargement and significant decrease in motor ability, the primary ciliary motor disorder hydrocephalus model is successfully constructed. This invention employs the above-mentioned novel method for constructing a primary ciliary motor disorder hydrocephalus model. The constructed hydrocephalus model exhibits good stability and repeatability, is objective and simple, and is highly operable, reducing other possible interfering factors. It provides a necessary experimental foundation for studying the mechanism of primary ciliary motor disorder hydrocephalus and developing treatment methods.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

Combination compositions of Compound 1 and fesoterodine for use in the treatment of neurological disorders, such as schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia, are described.

This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase (“LTA4H”) to treat and / or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.

The invention belongs to the field of medicinal chemistry, and discloses a 3-(2, 4-dihydroxyphenyl)-2H-chromene-2-ketone derivative and application thereof. According to the present invention, 3-(2, 4-dihydroxyphenyl)-2H-chromene-2-ketone is adopted as a lead compound to carry out corresponding structure optimization so as to obtain a series of 3-(2, 4-dihydroxyphenyl)-2H-chromene-2-ketone PDE2 inhibitor derivatives, and the general formula of the 3-(2, 4-dihydroxyphenyl)-2H-chromene-2-ketone PDE2 inhibitor derivatives is shown in the specification. The compounds show excellent inhibitory activity on PDE2, have significant application prospects for treating central nervous system diseases, have potential curative effects on improving memory deficit, improving learning and cognition functions, relieving dyskinesia and the like, can be used as key active ingredients, are used for researching and developing special pharmaceutical preparations for inhibiting PDE2 activity, and have broad application prospects. And a new way is expected to be opened up for the treatment of central nervous system diseases.

This invention relates to the field of natural language processing technology, specifically to a triage method and system for neurological diseases, comprising the following steps: segmenting the syntactic structure of the patient's chief complaint text sequence and identifying nodes; calculating and quantifying the nesting degree of the patient's linguistic organization logic; and obtaining a syntactic potential depth value. This invention can filter out noise interference from complex clinical expressions and extract neurological syndrome features by comparing them with a preset internal capsule lesion pattern. By jointly analyzing feature tensors pointing to limb paralysis with syntactic potential depth values ​​below the normal threshold, dual cross-validation of somatic motor disorders and central cognitive impairment is achieved. Furthermore, by comparing with feature thresholds of peripheral nerve or spinal cord lesions, the specificity of identifying central acute and severe illnesses such as ischemic stroke is improved, optimizing the accuracy of emergency triage.

In one embodiment of the present invention, the present invention relates to a pharmaceutical composition for treating an individual having a disorder selected from communication disorders, motor impairments, cognitive impairments, mental disorders, sensory disorders, autism spectrum disorders, and pervasive developmental disorders, the pharmaceutical composition comprising L-serine or a pharmaceutically acceptable salt thereof.

The present invention provides methods for screening for nucleotide sequences encoding the capsid of adeno-associated virus ("AAV") particles capable of infecting neurons or subcompartments thereof in a subject, including neurons derived from induced pluripotent stem cells or embryonic stem cells. The present invention also provides AAV capsids, nucleotide sequences encoding the capsids, expression vectors, viral particles, cells, and kits for use in methods for treating neuromuscular or neuromotor disorders (e.g., spasticity). Sequences generated by these methods may lead to new gene therapies that offer high specificity that can be personalized to the subject because they are targeted to select neuronal populations, such as motor neurons that innervate muscle cells.

This invention relates to the treatment of glucose transporter type 1 deficiency syndrome (Glut1-DS). In particular, the invention relates to specific medium-chain triglyceride compositions, enriched for C10 (decanoic acid), for use in treating movement disorders in Glut1-DS patients.

Provided is use of typhaneoside in preparing a medicament for treating ischemic stroke. Experiments have proved that typhaneoside can reduce the cerebral infarction volume, increase the cerebral blood perfusion volume, improve nerve functions and ameliorate motor disorders, reduce ROS levels, and protect neurons, thereby effectively treating ischemic stroke.

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof, wherein - - - - -, R1, R2, R3a, R3b, R4a , R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present invention provides a composition that can be manufactured into a medical food formulation and applied to improve or alleviate pathological changes associated with Parkinson's disease, such as motor impairment, cognitive degeneration, inflammatory responses, and mitochondrial dysfunction, and can be used for daily nutritional supplementation and to slow disease progression in Parkinson's disease patients or high-risk groups. [Solution] The present invention relates to a probiotic cocktail medical food composition and its use in slowing the progression of Parkinson's disease, wherein the composition comprises (a) at least one probiotic having neuroprotective or metabolic modulating function, and (b) a combination of functional amino acids including four or more essential amino acids.

The invention relates to the technical field of medical rehabilitation training equipment, in particular to neurodyskinesia training equipment which comprises a bottom plate, a U-shaped support is fixed to the middle of the top face of the bottom plate, a shaft rod is fixed to the top of the U-shaped support, and the outer side of the shaft rod is rotationally sleeved with a first supporting plate and a second supporting plate. And two symmetrically-distributed transmission blocks are slidably connected into the second supporting plate, a cross beam is fixed between the bottoms of the two transmission blocks, a limiting mechanism is arranged on the outer side of the cross beam, and a driving mechanism is fixed to one end of the top face of the bottom plate. According to the device, the first supporting plate and the second supporting plate are spliced to form the seat, a patient sits on the seat and stretches the legs with boots into warm water, the legs drive the legs to automatically emerge from the water under the buoyancy action of the inflatable floating balls, bending of knees is exercised, warm water is conveyed into the boots through the water conveying hoses, and the patient can sit on the seat through the water conveying hoses. The lower limbs can be conveniently trained in a warm environment, and the training comfort of the patient can be improved.

The application discloses a limb recovery exercise device, which comprises a seat, a hanging arm, a foot fixing mechanism, a pull rope, a manual pulling mechanism and a horizontal driving mechanism, the seat is provided with the manual pulling mechanism and the hanging arm, the hanging arm is provided with a guide rope assembly, the guide rope assembly is provided with the pull rope, one end of the pull rope is provided with the foot fixing mechanism, the other end of the pull rope is connected with the manual pulling mechanism, and the hanging arm is provided with the horizontal driving mechanism for driving the horizontal movement of legs. Compared with the prior art, the training effect can be improved, the device is convenient to use, and is particularly suitable for patients with motor disorders on any side of upper and lower limbs.

The invention discloses a Clostridium strain with a prevention or treatment effect on neurodegenerative brain diseases and an application of the Clostridium strain. The Clostridium strain provided by the invention has a neuroprotective effect, has a remarkable improvement effect in animal models of degenerative brain diseases such as Parkinson's disease and Alzheimer's disease, and has the effects of relieving dyskinesia and non-dyskinesia in the animal models of Parkinson's disease, including cognitive impairment, gastrointestinal dysfunction and the like; therefore, the strain can be effectively applied to foods and medicines for preventing or treating neurodegenerative brain diseases including Parkinson's disease, Alzheimer's disease, cognitive function impairment and the like.

This disclosure provides a method for selecting parameters for stimulation of the thalamus using a deep brain stimulator to treat a motor disorder in a subject, such as paralysis of the upper limb and face muscles. Also provided are methods for treating motor disorder in a subject. Also provided is an implantable electrode lead for neuromodulation and recording, configured to provide targeted stimulation and / or recording to multiple anatomically distinct neural structures, specifically the thalamus, the motor cortex, and optionally, the corona radiata, using a single continuous elongate lead body.

This invention relates to the treatment of glucose transporter type 1 deficiency syndrome (Glut1-DS). In particular, the invention relates to specific medium-chain triglyceride compositions, enriched for C10 (decanoic acid), for use in treating movement disorders in Glut1-DS patients.

The application provides a method for treating autism spectrum disorder (ASD) based on terahertz wave intervention and application thereof. The method comprises the following steps: dividing mice into four groups according to groups, each group having two types of mice; testing baseline behaviors of anxiety, motor ability and social ability of each group of mice; after a set time of completion of baseline behavior testing, using a THz-VNS device to intervene in each group of mice by THz-VNS; after the mice wake up, behavior testing is performed after a set time of completion of THz-VNS intervention; and statistically analyzing the behavior testing results to obtain the intervention results of THz-VNS intervention on ASD. By comparing the behavior testing results of wild type and ASD model mice before and after intervention, it is proved that the intervention method can improve the anxiety abnormality, motor dysfunction and social dysfunction of ASD model mice, which indicates that the intervention method can be used for the treatment of ASD. Meanwhile, the intervention method has a wide influence on the nervous system function, so the intervention is not limited to the treatment of ASD, but can also be extended to various nervous system diseases.

The present disclosure relates to recombinant viral vectors, pharmaceutical compositions comprising such recombinant vectors, and methods of preventing and treating Parkinson's disease (PD). In particular, the present disclosure provides adeno-associated virus (AAV) vectors, i.e., AAV-PHPeB, capable of expressing hyaluronate synthase 2 (Has2) within the host brain across the blood brain barrier. The invention provides a method for producing the AAVs, and also provides a method for improving the content of hyaluronic acid (HA) in the brain by expressing Has2 for a long time in the brain so as to remarkably recover neuronal damage and relieve dyskinesia to prevent and treat Parkinson's disease.

In various embodiments methods and devices are provided for facilitating locomotor function and / or voiding of bladder and / or bowel in a subject with a neuromotor disorder. In certain embodiments the methods involve providing magnetic stimulation of the spinal cord at a location, frequency and intensity sufficient to facilitate locomotor function and / or voiding of bladder and / or bowel.

The invention discloses a normal form for a practical small-channel dry electrode brain-computer interface (BCI) and a decoding method of the normal form for the practical small-channel dry electrode BCI. According to the method, multiple excitation forms are introduced, so that the paradigm can induce coupling of electroencephalogram signals in multiple brain regions; according to the method, a Motor Preparation (MP) normal form is designed, instructions in a video are sent out in four modes of voice and character, pure voice, pure character and arrow, a subject focuses on the voice and character instructions broadcasted in the video, and various actions such as leftward and rightward natural turning and forward left foot and right foot moving are executed according to the instructions. The MP normal form can be used as a basis for designing a closed-loop BCI system, and external equipment such as an exoskeleton and a wheelchair can be controlled by decoding a motion preparation signal of a subject. The MP normal form and the corresponding decoding method can effectively assist the rehabilitation process of a dyskinesia patient or enhance the athletic ability of a healthy subject. The method has the characteristics of noninvasiveness, convenience, low cost and low delay, and is expected to be popularized to practical application and clinical rehabilitation scenes.

To provide a medical wearable device for alleviating symptoms of neurological movement disorders.SOLUTION: The multimodal wearable band 11 stimulates sensory neurons of the wrist or ankle using mechanical vibration to reduce the severity of tremor, rigidity, involuntary muscle contractions, and bradykinesia caused by neurological movement disorders. The device reduces the severity of the user's symptoms using the sensor 1107 that provides an output that is used by the processing unit 1101 to determine the user's stimulation pattern and to determine when the stimulation 13 is needed, and then using the one or more mechanical transducers 1105 to stimulate the user's neural pathways 1203 correspondingly. The device may also be adapted to integrate with third party devices.SELECTED DRAWING: Figure 1

An orally disintegrating pharmaceutical tablet comprising: between 0.1 and 21 wt % of cariprazine or its pharmaceutically acceptable salts, between 0.1 and 15 wt % of a disintegrant, between 0.1 and 5 wt % of colloidal silicon dioxide, between 0.1 and 10 wt % of a taste masking agent, between 0.1 and 5 wt % of a lubricant, and up to 100 wt % of a diluent, the percentage being expressed with regard to the total weight of the pharmaceutical tablet. Said composition for use in the treatment and / or prevention of pathological conditions which require the modulation of dopamine receptors, selected from the group of psychoses, drug abuse, cognitive impairment accompanying schizophrenia, mild-to-moderate cognitive deficits, dementia, psychotic states associated with dementia, eating disorders, attention deficit disorders, hyperactivity disorders in children, psychotic depression, bipolar disorder, paranoid and delusional disorders, dyskinetic disorders, anxiety, sexual dysfunction, sleep disorders, emesis, aggression and autism.

The application discloses a gene medicine for treating deafness-dystonia-optic neuropathy syndrome caused by TIMM8A gene defect and application. The medicine core is a modularly designed adeno-associated virus vector system which carries an expression cassette containing a tissue-specific promoter and a human TIMM8A treatment gene. The application realizes precise treatment through local minimally invasive injection according to different symptoms: AAV-Anc80L65-MYO15-TIMM8A is injected into the cochlea to treat sensorineural hearing loss; AAV2 / 4-Brn3b-TIMM8A is injected into the vitreous body of the eyeball to treat optic neuropathy; AAV9-hSyn-TIMM8A is injected into the central lateral ventricle to treat dystonia. Preclinical studies have confirmed that the strategy can efficiently express TIMM8A protein in the corresponding target cells, significantly repair hearing, visual and motor function defects, and correct mitochondrial dysfunction from the pathological mechanism.

The application discloses application of Dendrofin D in preparation of a medicine for preventing and / or treating Parkinson's disease, wherein the Parkinson's disease is caused by deficiency of a trace element, and the trace element is selenium; Dendrofin D can reduce MPP+-induced cell damage and damage of TH+ neurons in the substantia nigra, and can reduce motor disorders and non-motor disorders caused by Parkinson's disease; meanwhile, Dendrofin D and catalpol are combined to be applied in preparation of the medicine for preventing and / or treating Parkinson's disease, and the combination can effectively improve the protection on Parkinson's disease and related symptoms caused by the Parkinson's disease, has the effects of preventing and treating Parkinson's disease, and can improve motor disorders and non-motor disorders related to Parkinson's disease.

This disclosure presents an advanced oral cannabinoid formulation in drop form for fast-acting relief of multiple sclerosis (MS), utilizing absorption through the oral mucosa to enhance bioavailability. The formulation includes cannabinoids like CBD, CBG, and THC, combined with Hericium erinaceus extract and Vitamin D to boost therapeutic efficacy. It targets various MS subtypes, including relapsing-remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS), and progressive-relapsing (PRMS), addressing symptoms such as fatigue, motor issues, spasticity, cognitive impairments, and mood disorders. The cannabinoids activate CB1 and CB2 receptors, reducing excitatory signaling, muscle spasticity, and neuroinflammation. CBD and CBG further enhance neuroprotection by modulating dopamine receptor expression and uptake, promoting synaptic health. Hericium erinaceus and Vitamin D complement these effects, reducing neural and immune damage and improving mental well-being, providing a comprehensive therapeutic strategy for managing MS.